Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study

European Journal of Cancer

Volumn 39, Issue 14, 2003, Pages 2006-2011

  Verweij, J ^a   Van Oosterom, A ^b   Blay, J Y ^c   Judson, I ^d   Rodenhuis, S ^e   Van Der Graaf, W ^f   Radford, J ^g   Le Cesne, A ^h   Hogendoorn, P C W ⁱ   Di Paola, E D ^j   Brown, M ^j   Nielsen, O S ^k  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j EORTC DATA CENTER   (Belgium)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

Gastrointestinal stroma tumours; Imatinib mesylate; Sarcoma

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; EVALUATION; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GRANULOCYTOPENIA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NAUSEA; PERIORBITAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SOFT TISSUE SARCOMA; VOMITING; DISEASE COURSE; GASTROINTESTINAL TUMOR; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; SARCOMA; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0142121411     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00836-5     Document Type: Article

References (19)

1. Brennan M.F., Alektti K.M., Maki R.G. Soft tissue sarcomas. DeVita V.T., Hellman S., Rosenberg S.A. Cancer Principles and Practice of Oncology. 6th edn. 2001;1841-1890 Lippincott, Williams and Wilkins, Philadelphia.
2. Flugstad D.L., Wilke C.P., McNutt M.A.et al. Importance of surgical resection in the successful management of soft tissue sarcoma. Arch. Surg. 134:1999;856-861.
3. O'Sullivan B., Wylie J., Catton C., Gutierrez E., Swallow C.J., Wunder J. The local management of soft tissue sarcoma. Semin. Radiat. Oncol. 9:1999;328-348.
4. Dirix L.Y., van Oosterom A.A.T. Soft tissue sarcomas in adults. Curr. Opin. Oncol. 11:1999;285-295.
5. Tepper J.E., Suit H.D. Radiation therapy of soft tissue sarcomas. Cancer. 55:1985;2273-2277.
6. Verweij J., Mouridsen H.T., Nielsen O.S.et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults. the EORTC point of view Crit. Rev. Oncol. Hematol. 20:1995;193-201.
7. Benjamin R.S., Legha S.S., Patel S.R.et al. Single agent ifosfamide studies in sarcomas of soft tissue and bone. the MD Anderson experience Cancer Chemother. Pharmacol. 31(Suppl. 2):1993;174-179.
8. Schoenfeld D.A., Rosenbaum C., Hortom J.et al. A comparison of Adriamycin versus vincristine and Adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 50:1982;2757-2762.
9. Borden E.C., Amato D.A., Rosenbaum C.et al. Randomised comparison of three Adriamycin regimens for metastatic soft tissue sarcomas. J. Clin. Oncol. 5:1987;840-850.
10. Santoro A., Tursz T., Mouridsen H.et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas. a randomised study of the EORTC Soft Tissue and Bone Sarcoma Group J. Clin. Oncol. 13:1995;1537-1545.
11. Mietinnen M., Sarlomo-Rikala M., Lasota J. Gastrointestinal stromal tumors. recent advances in understanding of thier biology Hum. Pathol. 30:1999;1213-1220.
12. Van Oosterom A.T., Judson I., Verweij J.et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors. a phase I study Lancet. 358:2001;1421-1423.
13. Demetri G.D., von Mehren M., Blanke Ch.et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480.
14. Therasse P., Arbuck S.G., Eisenhauer E.A.et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer I. 92:2000;205-216.
15. Graadt van Roggen J.F., Van Velthuysen M.L.F., Hogendoorn P.C.W. The histopathological differential diagnosis of gastrointestinal stromal tumours. J. Clin. Pathol. 54:2001;96-103.
16. Druker B.J., Talpaz M., Resta D.J.et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 344:2002;1084-1086.
17. Savage D.G., Antman K.A. Imatinib mesylate. a novel oral targeted therapy N. Engl. J. Med. 346:2002;683-693.
18. Blanke C.D., von Mehren M., Joensuu H.et al. Evaluation of the safety and efficacy of an oral molecularly targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-KIT (CD117). Proc. Am. Soc. Clin. Oncol. 20:2001;1a.
19. Van Glabbeke M., Verweij J., Judson I., Nielsen O.S. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur. J. Cancer. 38:2002;543-549.